Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Mansi Arora, Justin Moser, Timothy E. Hoffman, et al.
Cell (2023) Vol. 186, Iss. 12, pp. 2628-2643.e21
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Catherine Dietrich, Alec Trub, Antonio Ahn, et al.
Cancer Discovery (2023) Vol. 14, Iss. 3, pp. 446-467
Open Access | Times Cited: 45
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
R. Gerosa, Rita De Sanctis, Flavia Jacobs, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104324-104324
Open Access | Times Cited: 20
Role of LMO7 in cancer (Review)
Qun Zeng, Tingting Jiang, Jing Wang
Oncology Reports (2024) Vol. 52, Iss. 3
Closed Access | Times Cited: 16
Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest
Reece Foy, Lisa Crozier, Aanchal Udaynath Pareri, et al.
Molecular Cell (2023) Vol. 83, Iss. 22, pp. 4047-4061.e6
Open Access | Times Cited: 34
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
JACS Au (2024) Vol. 4, Iss. 5, pp. 1911-1927
Open Access | Times Cited: 10
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Jae Hyun Kim, et al.
(2025)
Open Access | Times Cited: 1
Transient silencing of hypermutation preserves B cell affinity during clonal bursting
Juhee Pae, Niklas Schwan, Bertrand Ottino-Löffler, et al.
Nature (2025)
Open Access | Times Cited: 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Rei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1919-1935.e9
Open Access | Times Cited: 6
Cancer takes many paths through G1/S
Erik S. Knudsen, Agnieszka K. Witkiewicz, Seth M. Rubin
Trends in Cell Biology (2023) Vol. 34, Iss. 8, pp. 636-645
Closed Access | Times Cited: 15
Cyclers’ kinases in cell division: from molecules to cancer therapy
Giacomo Milletti, Valeria Colicchia, Francesco Cecconi
Cell Death and Differentiation (2023) Vol. 30, Iss. 9, pp. 2035-2052
Open Access | Times Cited: 14
Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform
Fanye Meng, Jinxin Liu, Zhongying Cao, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107285-107285
Closed Access | Times Cited: 4
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma
Lin Dong, Chao Liu, Haoyang Sun, et al.
Cancer Letters (2024) Vol. 593, pp. 216956-216956
Closed Access | Times Cited: 4
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery
Shen Xiao-juan, Shijia Yan, Tao Zeng, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Interactions between lncRNAs and cyclins/CDKs complexes; key players in determining cancer cell response to CDKs inhibitors
Bahaa Ibrahim Saeed, Abhinav Kumar, Enwa Felix Oghenemaro, et al.
Experimental Cell Research (2025) Vol. 445, Iss. 2, pp. 114406-114406
Closed Access
Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5'- and 3'-ends
Olivia Luyties, Lynn Sanford, Jessica Rodino, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
CDK2 activity crosstalk on the ERK kinase translocation reporter can be resolved computationally
Timothy E. Hoffman, Chengzhe Tian, Varuna Nangia, et al.
Cell Systems (2025) Vol. 16, Iss. 1, pp. 101162-101162
Closed Access
Discovery of 2,4-Quinazolinedione Derivatives as LC3B Recruiters in the Facilitation of Protein Complex Degradations
Yanping Zeng, Jian Xiao, Shi Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117293-117293
Closed Access
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Jae Hyun Kim, et al.
(2025)
Open Access
Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future.
Rosalba Torrisi, R. Gerosa, Chiara Miggiano, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104634-104634
Closed Access
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Licoisoflavone a Inhibits Colorectal Cancer Cell Proliferation Through Targeting Cdk2-Cyclin E1 Axis-Mediated Cell Cycle Transition
Jingwei Cui, Hao Chen, Yuru Chen, et al.
(2025)
Closed Access
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Taylor Jones, Junjie Feng, Olivia Luyties, et al.
Science Advances (2025) Vol. 11, Iss. 9
Open Access
Page 1 - Next Page

Scroll to top